22583-90-0Relevant articles and documents
Discovery and structural analyses of S-adenosyl-l-homocysteine hydrolase inhibitors based on non-adenosine analogs
Nakao, Akira,Suzuki, Hiroko,Ueno, Hiroaki,Iwasaki, Hiroshi,Setsuta, Tomofumi,Kashima, Akiko,Sunada, Shinji
, p. 4952 - 4969 (2015/08/03)
Optimization of a new series of S-adenosyl-l-homocysteine hydrolase (AdoHcyase) inhibitors based on non-adenosine analogs led to very potent compounds 14n, 18a, and 18b with IC50 values of 13 ± 3, 5.0 ± 2.0, and 8.5 ± 3.1 nM, respectively. An X-ray crystal structure of AdoHcyase with NAD+ and 18a showed a novel open form co-crystal structure. 18a in the co-crystals formed intramolecular eight membered ring hydrogen bond formations. A single crystal X-ray structure of 14n also showed an intramolecular eight-membered ring hydrogen bond interaction.
THERAPEUTIC AGENT FOR CEREBRAL INFARCTION
-
, (2012/08/08)
The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.
Probing the proposed phenyl-A region of the sigma-1 receptor.
Ablordeppey, Seth Y,Fischer, James B,Law,Glennon, Richard A
, p. 2759 - 2765 (2007/10/03)
The proposed phenyl-A region of sigma (sigma) receptors accommodates several structural features. In this study we explored the possibility that appropriate structural features located at the phenyl-A region of sigma receptor sites could lead to more potent and selective agents for the sigma receptor subtypes. By keeping the phenyl-B substituent as the optimum omega-phenylpentyl moiety, and varying substituents in the phenyl-A region, we have observed changes in binding potency and selectivity at the sigma receptor subtypes. SAR for the binding of these compounds at sigma-2 sites was also examined.
Bicyclo-substituted phenylacetonitrile derivatives
-
, (2008/06/13)
The invention relates to compounds of the formula: STR1 which are useful cardiovascular agents.
Bicyclo-substituted phenylacetonitrile derivatives
-
, (2008/06/13)
The invention relates to compounds of the formula: STR1 which are useful cardiovascular agents.